Ogeda SA: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes   Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes   Primary end points met with significant reduction versus placebo seen...

Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364 Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364  Ogeda, a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting...